AAVE's price reached a year-to-date high of $185, driven by strong gains in long positions on the Hyperliquid platform. Four separate long positions each showed unrealized profits exceeding $1 million, highlighting significant investor confidence and momentum in the asset. This surge reflects growing interest in AAVE within the digital asset market, potentially attracting more traders and investors.
While AAVE hit a year-to-date high of $185 as noted in the article, on Pluang it trades at Rp3.307.259 with a strong 1-day gain of 11.89% as of Oct 02, 2026 14:31 WIB. This contrasts with its typical hold time of 105 days on the platform, indicating active trading interest. The market cap stands at Rp50,85 trillion, supported by a 24-hour volume of Rp12,14 trillion and a buy order dominance of 60%.
An attacker exploited a flaw in the FlashLoopAdapter, a third-party Safe module managing leveraged Aave v3 positions, to steal about $305,000 from two Ethereum Safe wallets. The attacker bypassed access controls by using a fake Safe contract, repaid ...
Aave (AAVE) saw its price rise 4.16% within one hour to $182 on October 2, with a total 24-hour gain of 8.11%. During the same hour, short liquidations across Binance, Bybit, and OKX exchanges reached $350,000, while no long liquidations occurred. Aa...
An attacker exploited security flaws in Aave V3's Loop Safe Module, specifically targeting the FlashLoopAdapter contract's open() and close() functions. This breach allowed unauthorized access and execution, resulting in the theft of about 114.09 Eth...
Aave led altcoin gains with a 9.14% rise to $176.21, driven by increased trading and platform updates. Meanwhile, Quant fell sharply by 14.33%, reflecting the volatile and divergent trends in the altcoin market. Other altcoins showed mixed results, w...
The AAVE cryptocurrency token briefly surpassed $178 on October 2, marking its highest price since February. It gained 8.83% over the previous 24 hours, trading around $176.15 after crossing the $178 threshold. This price movement signals renewed inv...
